Chronic Kidney Disease Drug Market Projected to Reach $4 Billion by 2034 with US Accounting for 59.7 Percent of Sales in 2024

The market for Chronic Kidney Disease-related Hyperparathyroidism (CKD-HPT), Hyperphosphatemia (HP), and Hyperkalemia (HK) is projected to reach $4 billion across seven major markets (7MM) by 2034. In 2024, the United States accounted for the largest share of this market, generating $1.5 billion in drug sales, which represented 59.7% of total sales across these regions.

The seven major markets include the United States, as well as key regions in Europe and Asia-Pacific. The U.S. led the market in 2024 due to its significant patient population and access to advanced therapies targeting CKD-HPT, HP, and HK conditions. These diseases are commonly associated with chronic kidney disease and require specialized treatments to manage complications effectively. The report highlights that this sector will continue to grow over the next decade as demand for innovative therapies increases globally.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 2, 2025

Related posts:

Analysis reveals rise in claim denial rates for cancer-related advanced genetic testing HER3 Identified as Key Player in Therapy Resistance Across Multiple Solid Tumors AliveDx Submits 510(k) Application to FDA for MosaiQ AiPlex Vasculitis Diagnostic Test Study Examines Electromyographic Activity of Orbicularis Oculi Muscle in Lower Eyelid Function and Ptosis

Author

GOAI